92199-49-0

Upstream product

• 2835-95-2 amino-4 hydroxy-2 toluene 
• 98-88-4 benzoyl chloride 
• 723257-05-4 C₂₁H₁₇NO₃ 

Downstream Products

• 929291-19-0 3-(5-benzoylamino-2-methyl-phenoxymethyl)-4-chloro-thieno[3,2-c]pyridine-7-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

Discovery of meta-amido bromophenols as new antitubercular agents

A series of meta-amido bromophenol derivatives were designed and synthesized. The compounds were found to potently inhibit the growth of Mycobacterium tuberculosis H37Ra. They also exhibited moderate inhibitory activity against Mycobacterium tuberculosis H37Rv and multidrug-resistant strains. The compounds did not show inhibitory activity against normal Gram-positive and Gram-negative bacteria. Moderate cytotoxicities and good metabolic stability were observed for the selected compounds. The results demonstrated meta-amido bromophenols as a new class of antitubercular agents with good potentials.

σ2P,O-hybrid ligands: Synthesis of the first 4-hydroxy-1,3-benzazaphospholes by ortho-lithiation of M-amidophenyl diethyl phosphates

The m-phosphorylanilides 2 are available from anilides 1 by the Atherton-Todd reaction; the selective ortho-lithiation of the o'-methyl-protected phosphorylpivalanilide 2b with tBuLi proceeded in high yield in the presence of ClSiMe3. The ortho-lithiation is followed by rapid 1,3-migration of the PO3Et2 group to yield the phosphonoanilide cis/trans-3b. This compound mainly reacts with excess LiAlH4 by reductive cyclization to form the 4-hydroxy-1H-1,3-benzazaphosphole 6. The lithiation of the o'-unprotected phosphorylpivalanilide 2a with LDA was unselective and led to 3a and 4a in low yields, whereas additional ortho-lithiation of the benzoyl group occurred for the lithiation of the o'-protected phosphonobenzanilide 2c with tBuLi/LDA to give 7 in rather low yield. The reduction of crude 7 led to (benzylamino)phenol 8 and the 4-hydroxy-1H-1,3-benzazaphosphole 9 as a minor product. The properties, NMR spectroscopy data, and crystal structures of 5b, 6, and 8 are reported.

4-amino-thieno[3,2-c] pyridine-7-carboxylic acid derivatives

The present invention relates to compounds of the formula medicaments containing them and the use of these compounds as pharmaceutically active agents. The compounds exhibit activity as Raf kinase inhibitors and therefore may be useful for the treatment of diseases mediated by said kinases, especially as anticancer agents.